Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
Conditions
Keywords
Immunotherapy, CD47, SIRPα, Solid Tumor, Lymphoma
Brief summary
The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Detailed description
This is an open-label, multi-center, dose-escalation, Phase 1 study. This study is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity, and identification of maximum tolerated dose (MTD) of HCB101 intravenous injection in adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. Eligible subjects must have failed standard therapies, been intolerable, or been considered medically inappropriate by the investigator. Subjects will be treated until unacceptable AEs, radiographic or clinical documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study, whichever occurs first.
Interventions
DRUGHCB101
HCB101 administered via. intravenous (IV) infusion.
Sponsors
FBD Biologics Limited
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Able to understand and willing to sign the ICF. 2. Male and female subjects of ≥18 years of age. 3. Histologically/cytologically confirmed, locally advanced solid tumor: subjects with histologically or cytologically confirmed advanced solid tumors refractory to standard therapy, or for which no standard treatment exists or non-Hodgkin lymphoma, relapsed or refractory to at least 2 prior lines of therapy. 4. For subjects with advanced solid tumor - must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at baseline. 5. For subjects with non-Hodgkin lymphoma - must have non-Hodgkin lymphoma that is measurable or assessable for response per Lugano Classification (with 2016 refinement). 6. Must have ECOG performance status of 0 to 2 at Screening. 7. Able to provide tumor tissue samples. 8. Have life expectancy of ≥12 weeks.
Exclusion criteria
1. With known history of hypersensitivity to any components of HCB101. 2. Known active or untreated CNS metastases and/or carcinomatous meningitis. 3. Have undergone a major surgery or radical radiotherapy or palliative radiotherapy or have used a radioactive drug that is not completed at least 2 weeks prior to the first dose of HCB101. 4. Clinically significant cardiovascular condition. 5. Any previous treatment-related toxicities which have not recovered to ≤ Grade 1 as evaluated by National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia. 6. With known inherited or acquired bleeding disorder or bleeding diathesis. . 7. Have RBC transfusion within 4 weeks prior to Screening. 8. With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months. 9. Any investigational or approved systemic cancer therapy. 10. Active use of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on case by case basis. There will be no restriction for daily aspirin ≤ 81 mg/QD. 11. Have used herbal medication within 14 days prior to the first dose of HCB101. 12. Have received any treatment targeting the CD47 or SIRPα pathway. 13. Have other malignancies requiring treatment within 2 years prior to the first dose of HCB101. 14. Participation in another clinical study with an investigational product administered in the last 14 days prior to receiving the first dose of HCB101. 15. An investigational device used within 28 days prior to the first dose of HCB101. 16. Positive for hepatitis B, active hepatitis C infections, positive for HIV, or known active or latent tuberculosis. 17. Known to have a history of alcoholism or drug abuse.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number/incidence and percentage of subjects with adverse events, including ADA. | 12 months | To evaluate the safety and tolerability of HCB101 |
| Number of subjects with MTD of HCB101 | 12 months | To evaluate the safety and tolerability of HCB101 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Rate Response (ORR) | 12 months | ORR is defined as the proportion of participants who have a partial response (PR) or critical response (CR) |
| Duration of Response (DoR) | 12 months | DOR is defined as time from date of initial documentation of a response (PR or CR) to date of first documented evidence of progressive disease (PD) |
| Disease Control Rate (DCR) | 12 months | DCR is defined as the proportion of participants who have a partial response (PR), critical response (CR), or disease stable (SD) |
| Progression-Free Survival (PFS) | 12 months | Defined as the duration from the start of treatment until tumor progression or death of any cause. |
| Peak Plasma Concentration (Cmax) of HCB101 | 12 months | Peak Plasma Concentration (Cmax) of HCB101 following single and repeated IV doses of HCB101 at different dose levels. |
| Area under the plasma concentration versus time curve (AUC) of HCB101 | 12 months | Area under the plasma concentration versus time curve (AUC) of HCB101 following single and repeated IV doses of HCB101 at different dose levels. |
| Time to maximum drug concentration in plasma (Tmax) of HCB101 | 12 months | Time to maximum drug concentration in plasma (Tmax) of HCB101 following single and repeated IV doses of HCB101 at different dose levels. |
| Terminal elimination half-life (t1/2) of HCB101 | 12 months | Terminal elimination half-life (t1/2) of HCB101 following single and repeated IV doses of HCB101 at different dose levels. |
Countries
China, Taiwan, United States
Contacts
CONTACTFBD Clinical
Outcome results
None listed